Mo Neuro222 retweeted
FDA approves asundexian + antiplatelets after non-cardioembolic ischaemic stroke/high-risk TIA.
OCEANIC-STROKE: ischaemic stroke 6.2% vs 8.4%.
Bleeding precautions remain. Not approved for AF stroke prevention.
Mo Neuro222 retweeted
"I sit in my room, surrounded by silence, but inside me there is a storm that never stops."
— Franz Kafka, Diaries, 1913
Mo Neuro222 retweeted
Obesity in children with #IBD is the new elephant in the room
This timely review in @JPGNonline explores the growing challenge of obesity in children with IBD:
✅ Beyond undernutrition, impaired growth, and delayed puberty, it's time to also consider obesity in children with IBD
❗Excess adipose tissue may adversely affect disease presentation, outcomes, and treatment response
✅ Body mass index is not enough as a measure of body composition
✅ Children with IBD exhibit poorer diet quality with:
🔸 high ratio of animal-to-plant protein
🔸 high ratio of omega-6 to omega-3 fatty acid intake
🔸 ⬇️ fiber intake
🔸 ⬇️ iron
🔸⬇️ zinc
🔸 ⬇️ vitamin D
📚 Read the full review here: onlinelibrary.wiley.com/doi/…
Mo Neuro222 retweeted
Encouraging news for pancreatic cancer!
At ENA 2026, daraxonrasib (an oral RAS inhibitor) + gemcitabine/nab-paclitaxel showed promising first-line results in metastatic pancreatic cancer (61 patients):
• Tumor shrinkage in 61% of patients (ORR), including 8% complete responses
• Median PFS of 12.8 months
• 77% alive at one year
For context, historical results with gemcitabine/nab-paclitaxel (MPACT) showed a 23% response rate and 5.5-month median PFS.
Very encouraging, but this was a small, nonrandomized study. The phase 3 RASolute-303 trial will help determine whether adding daraxonrasib truly improves outcomes.
Mo Neuro222 retweeted
🩸 Portal vein thrombosis affects 1 in 10 hospitalized patients with cirrhosis worldwide.
🌍 In the CLEARED cohort (n=7,721), PVT independently predicted 30-day mortality (OR 1.5) and was linked to more complications.
doi.org/10.1097/LVT.00000000…
#LiverTwitter
Mo Neuro222 retweeted
📑 ApiHep RCT: Adding apixaban to standard medical treatment in Child-Pugh B7-C10 cirrhosis
⬇️ 1-yr hepatic decompensation (33.1% vs 54.3%)
🩸 without increased bleeding risk‼️
ovid.com/10.1097/HC9.0000000…
@ebtapper @HepCommJournal @aiims_newdelhi
Mo Neuro222 retweeted
We have just updated our distal hereditary motor neuropathy genetics checklist with this paper neurochecklists.com/explore/…
Mo Neuro222 retweeted
Atypical Cogan syndrome associated with marginal zone lymphoma presenting with unusual ocular findings and central nervous system vasculitis: a case report
link.springer.com/article/10…
Mo Neuro222 retweeted
This review highlights the molecular drivers of synaptic transmission breakdown and glia-neuron disruption in neurodegenerative diseases, underscoring therapeutic opportunities to preserve synaptic plasticity and halt cognitive and motor decline.
Mo Neuro222 retweeted
Beyond Bicarbonate: Renal Replacement Therapy in Refractory Diabetic Ketoacidosis: A Narrative Review
CCR Journal Watch
criticalcarereviews.com/late…
Mo Neuro222 retweeted
Dural Rosai–Dorfman-disease in H syndrome: expanding the neuropathologic spectrum of SLC29A3-related disease
link.springer.com/article/10…
Outcomes of spontaneous portosystemic shunt embolization for hepatic encephalopathy in cirrhosis—the OPAL study link.springer.com/article/10… @hepinternation1
Mo Neuro222 retweeted
Today's Paper of the Day is:
Redefining blood pressure targets in refractory septic shock
criticalcarereviews.com/late…
Join us to read 1 paper per day and stay up-to-date as we cover the spectrum of critical care across 2026
Mo Neuro222 retweeted
Lancet Neurologyに神経障害性疼痛のメカニズム、診断、治療についての包括的な総説が載った
Open Access
#neuropathic_pain
#papers
thelancet.com/journals/laneu…
Mo Neuro222 retweeted
We have just updated our refractory epilepsy features checklist with this paper neurochecklists.com/explore/…
Mo Neuro222 retweeted
Kierkegaard's The Concept of Anxiety looks into how freedom is at once a blessing and a curse.
The more possibilities that exist for us, the more overwhelming existence becomes.
Mo Neuro222 retweeted
CRITICAL PHYSIOLOGY SERIES #131: Infratentorial Stroke and Posterior Fossa Edema
A patient with cerebellar stroke suddenly becomes drowsy. In the posterior fossa, small increases in volume can be fatal.
The rigid posterior fossa contains the cerebellum, brainstem and fourth ventricle. Ischemic energy failure triggers cytotoxic and subsequent vasogenic edema; hemorrhage adds hematoma mass effect. Expansion compresses the brainstem and obstructs CSF flow, producing acute hydrocephalus, raised intracranial pressure and herniation.
Risk increases with large cerebellar infarcts, bilateral or vermian involvement, brainstem injury and hemorrhagic transformation. A cohort linked infarct volumes near 38 mL to malignant swelling, but this is not an absolute threshold.
Diagnosis: Vertigo, vomiting, ataxia or dysarthria may precede reduced consciousness, abnormal pupils and respiratory instability. Low NIHSS scores can be misleading. Urgent CT excludes hemorrhage but may miss early posterior fossa ischemia; CTA evaluates arterial occlusion, while DWI-MRI improves detection. Early serial imaging must assess fourth-ventricle effacement, hydrocephalus and brainstem compression.
Management: Provide close neurological monitoring and early neurosurgical consultation. Protect the airway and maintain oxygenation, perfusion and normothermia. Offer reperfusion to eligible ischemic stroke patients; reverse anticoagulation promptly in hemorrhage. Hyperosmolar therapy can bridge deterioration but must not delay definitive surgery.
The 2026 AHA/ASA guideline recommends ventriculostomy for obstructive hydrocephalus after cerebellar infarction. Suboccipital decompression is recommended for deterioration from brainstem compression or infarct volume ≥35 mL. For cerebellar hemorrhage, deterioration, compression, hydrocephalus or hematoma ≥15 mL warrants urgent evacuation, with or without ventricular drainage.
Deteriorating examination in posterior fossa stroke is a time-critical surgical warning.
Recommended lectures 📚
Prabhakaran et al. Stroke (2026). doi.org/10.1161/STR.00000000…
Greenberg et al. Stroke (2022). doi.org/10.1161/STR.00000000…
Baki et al. Stroke Vasc Neurol (2025). doi.org/10.1136/svn-2024-003…
Tanaka et al. J Clin Med (2025). doi.org/10.3390/jcm14248663
Moniche et al. Neurologia (Engl Ed) (2026). doi.org/10.1016/j.nrleng.202…
#CriticalPhysiology #NeurocriticalCare #Stroke #CerebralEdema

































